Insider · CIK 0001977474
Donna Carroll
Files at BGSF (BGSF, INC.). First filing -, latest -.
In brief
Donna Carroll files SEC Form 4 as director at BGSF (BGSF, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Donna Carroll has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +3,360 | $0.00 | $0 | 50,391 | Aug 6, 2026 |
| Aug 4, 2026 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 1,000 | Aug 6, 2026 |
| Aug 4, 2026 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 2,000 | Aug 6, 2026 |
| Aug 4, 2026 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 3,000 | Aug 6, 2026 |
| Aug 4, 2026 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 4,000 | Aug 6, 2026 |
| Aug 4, 2026 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 5,000 | Aug 6, 2026 |
| May 6, 2026 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +3,691 | $0.00 | $0 | 43,531 | May 7, 2026 |
| Feb 4, 2026 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +3,354 | $0.00 | $0 | 39,840 | Feb 6, 2026 |
| Nov 5, 2025 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +5,482 | $0.00 | $0 | 35,486 | Nov 7, 2025 |
| Aug 5, 2025 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +2,686 | $0.00 | $0 | 30,004 | Aug 7, 2025 |
| Aug 5, 2025 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 1,000 | Aug 7, 2025 |
| Aug 5, 2025 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 2,000 | Aug 7, 2025 |
| Aug 5, 2025 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 3,000 | Aug 7, 2025 |
| Aug 5, 2025 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 4,000 | Aug 7, 2025 |
| Aug 5, 2025 | BGSF BGSF, INC. | AGrant or award Stock Optionsderivative | +1,000 | $0.00 | $0 | 5,000 | Aug 7, 2025 |
| May 7, 2025 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +5,859 | $0.00 | $0 | 25,818 | May 9, 2025 |
| Feb 5, 2025 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +3,613 | $0.00 | $0 | 19,959 | Feb 7, 2025 |
| Nov 6, 2024 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +2,435 | $0.00 | $0 | 16,346 | Nov 8, 2024 |
| Feb 7, 2024 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +1,831 | $0.00 | $0 | 7,712 | Feb 9, 2024 |
| Nov 8, 2023 | BGSF BGSF, INC. | AGrant or award Common Stock, $0.01 per share par value | +1,976 | $0.00 | $0 | 5,881 | Nov 13, 2023 |
Questions about Donna Carroll
Answered from the filings on this page, as of the latest one.
Is Donna Carroll buying or selling?
Donna Carroll has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Donna Carroll's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Donna Carroll has 0.
Where does Donna Carroll file Form 4?
Donna Carroll has filed Form 4 at BGSF (BGSF, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.